BIIB Share Price

Open 285.01 Change Price %
High 285.81 1 Day 0.38 0.13
Low 266.00 1 Week -3.81 -1.32
Close 285.13 1 Month 11.89 4.35
Volume 549129 1 Year 22.78 8.68
52 Week High 333.65
52 Week Low 223.02
BIIB Important Levels
Resistance 2 303.49
Resistance 1 295.93
Pivot 278.98
Support 1 274.33
Support 2 266.77
NASDAQ USA Most Active Stocks
DRYS 2.24 -4.68%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ACAS 17.99 0.39%
ASTI 0.00 0.00%
More..
NASDAQ USA Top Gainers Stocks
MYRX 0.10 100.00%
LOCM 0.09 50.00%
CEMP 4.05 28.57%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
SKBI 0.10 25.00%
IPCI 2.55 18.60%
QKLS 0.15 15.38%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
GMETP 0.70 -59.54%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
EDMC 0.01 -50.00%
QTWW 0.08 -50.00%
SPIR 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
More..

Biogen Idec Inc. (NASDAQ: BIIB)

BIIB Technical Analysis 3
As on 24th Feb 2017 BIIB Share Price closed @ 285.13 and we RECOMMEND Buy for LONG-TERM with Stoploss of 284.14 & Buy for SHORT-TERM with Stoploss of 283.33 we also expect STOCK to react on Following IMPORTANT LEVELS.
BIIB Target for February
1st Target up-side 293.58
2nd Target up-side 305.04
3rd Target up-side 316.5
1st Target down-side 260.9
2nd Target down-side 249.44
3rd Target down-side 237.98
BIIB Other Details
Segment EQ
Market Capital 33194547200.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.biogenidec.com
BIIB Address
BIIB
225 Binney Street
Cambridge, MA 02142
United States
Phone: 781-464-2000
BIIB Latest News
Lookout for Price Target? Biogen Inc (BIIB), The Progressive Corp. (PGR)   StockNewsJournal   - 21st Feb 17
Did Biogen Inc. Shoot Itself in the Foot?   Motley Fool   - 21st Feb 17
How Biogen Inc (BIIB) Stock Could Gain Another 25%   Investorplace.com   - 08th Feb 17
Why Biogen Inc (BIIB) Stock Is a Solid Long-Term Bet   Investorplace.com   - 03rd Feb 17
Biogen Inc (BIIB) Stock Needs a Biotech Bounceback   Investorplace.com   - 01st Feb 17
Biogen: An Attractive Long In A Beaten-Down Industry   Seeking Alpha   - 31st Jan 17
Biogen Inc Makes Up for Lackluster Revenue Growth   Motley Fool   - 28th Jan 17
Why Did Biogen's Earnings Drop?   Seeking Alpha   - 27th Jan 17
Better Buy: Biogen Inc. vs. Gilead Sciences Inc.   Motley Fool   - 25th Jan 17
Biogen Inc (BIIB) Stock Enters Uncharted Waters   Nasdaq   - 25th Jan 17
Interactive Technical Analysis Chart Biogen Idec Inc. ( BIIB NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Biogen Idec Inc.
BIIB Business Profile
Biogen Idec Inc. (Biogen Idec) is a global biotechnology company. The Company discovers, develops, manufactures and markets therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. The Company’s products include AVONEX, TYSABRI, FAMPYRA, FUMADERM and RITUXAN. In September 2011, the Company acquired from the Dompe Group the noncontrolling interests in its joint venture sales affiliates in Italy and Switzerland. In April 2013, Elan Corporation, plc closed the TYSABRI (natalizumab) Collaboration Transaction with Biogen Idec.